Medicinal Cannabis for
ADHD & OCD
You've been prescribed medicinal cannabis to help manage symptoms that haven't fully responded to other treatments. This guide explains what THC and CBD actually do in your brain, what the science says, and how to use your medicine as safely and effectively as possible.
This document contains important information about your medicine. Take a few minutes to read it before you start, and keep it somewhere handy. If anything is unclear — or if you have questions after reading — your MedWest pharmacist is always available to help.
More than you might expect. Both involve a part of the brain called the endocannabinoid system — and that's exactly where medicinal cannabis works. Understanding this connection helps explain why your doctor has prescribed it.
ADHD affects how your brain manages attention, impulse control, and motivation. At its core it's a problem with dopamine — your brain's "get-things-done" chemical. The same circuits that regulate dopamine are densely packed with cannabinoid receptors (CB1), making them a genuine therapeutic target for cannabis-based medicines.4
OCD involves intrusive, unwanted thoughts and repetitive behaviours that feel impossible to resist. Preclinical research shows that abnormal function in the brain's endocannabinoid system — particularly in circuits governing habit and threat response — directly contributes to compulsive behaviour. These circuits are an active and promising area of cannabinoid research.3,6
Medicinal cannabis works through two main compounds. They act on your brain differently and often complement each other. Here's what each one does — and why it matters for your condition. Tap through to the science notes below each point if you'd like more detail.
- Calms your brain's alarm centre — reducing fear, threat perception, and anxiety Activates CB1 receptors in the amygdala; validated in human neuroimaging studies5,7
- Supports the dopamine signalling pathways most affected in ADHD CB1 receptors modulate dopamine transmission in the basal ganglia and neocortex4
- May help reduce compulsive urges by modulating habit-forming circuits in the brain CB1 activity in the dorsolateral striatum regulates extinction of compulsive procedural behaviour6
- Can improve sleep quality — important for both ADHD and OCD, where disrupted sleep worsens symptoms Short-term THC associated with reduced sleep onset latency; reviewed in multiple sleep literature sources9
- Important: High doses can increase anxiety rather than reduce it — always start low A bidirectional dose-response on anxiety is well-established in the literature10
- Reduces anxiety through your serotonin system — the same pathway targeted by antidepressants Partial agonist at 5-HT1A serotonin receptors; meta-analysis effect size Hedges' g = −0.92 for anxiety10
- Boosts your brain's own calming chemicals by slowing their natural breakdown Inhibits fatty acid amide hydrolase (FAAH), increasing endogenous anandamide levels11
- Shown to reduce compulsive behaviour in research models — to a level comparable to SSRI medication CBD reversed compulsive marble-burying in mice to a level matching fluoxetine at equivalent doses6
- Helps regulate the brain's fear-extinction pathway — relevant to the anxiety loop in OCD and attention dysregulation in ADHD Enhances fear extinction consolidation via CB1 receptors in dorsal hippocampus and medial prefrontal cortex12
Your Brain Already Has a Cannabinoid System
Most people don't realise this, but your brain naturally produces its own cannabis-like molecules — called endocannabinoids — and has specific receptors (CB1 and CB2) built to receive them. This is called the Endocannabinoid System (ECS), and it acts like a master regulator across the brain, helping balance mood, memory, fear, habit, and attention.
In ADHD and OCD, this system becomes dysregulated — parts of it go quiet when they should be active, or stay switched on when they should turn off. THC and CBD work by gently restoring that balance in the brain regions most disrupted by your condition: the amygdala (fear and emotion), hippocampus (memory), prefrontal cortex (decision-making), and basal ganglia (habit and compulsion).4,6
Attention & motivation
Cannabis targets the exact brain circuits that regulate dopamine — the chemical at the heart of focus, motivation, and impulse control.
CB1 receptors are densely expressed in dopaminergic pathways of the basal ganglia and neocortex — regions directly implicated in ADHD. The UK Medical Cannabis Registry found significant improvements in anxiety and quality of life across ADHD patients followed for 12 months of treatment.4,13
Hyperactivity & impulsivity
The only placebo-controlled trial of cannabinoids in ADHD found meaningful improvements in restlessness and the ability to pause before acting.
Cooper et al. RCT (n=30): nabiximols (1:1 THC:CBD) produced significant improvements in hyperactivity/impulsivity (p=0.03) and response inhibition compared to placebo. The study was underpowered, which highlights the need for larger trials.14
Compulsive behaviours
The drive to carry out compulsions is partly regulated by a brain circuit that cannabinoids directly target. Both CBD and THC have shown anti-compulsive effects in research settings.
CB1 receptor activity in the dorsolateral striatum is required for extinction of compulsive procedural behaviour. CBD produced anti-compulsive effects in animal studies equivalent to fluoxetine. Dronabinol (oral THC) produced relief in multiple treatment-refractory OCD case reports.6,15
Obsessions & the anxiety loop
OCD and fear are closely linked — obsessive thoughts usually trigger an intense threat alarm. Cannabinoids may help break this cycle, especially when paired with psychological therapy.
Impaired fear extinction is a documented neurobiological feature of OCD. A pilot RCT found nabilone (a THC analogue) may augment exposure-based psychotherapy outcomes. One case documented full OCD remission following 20 months of medicinal cannabis treatment.15,16
Finding the right dose takes time, and that's completely normal. The ranges below reflect what's been used in Australian clinical practice and the research literature. Always begin at the lowest prescribed dose — you can gradually increase, but you can't undo a dose that's too high.
⚠ Please read this section carefully
Do not drive until you know how this medicine affects you. THC impairs driving ability — this is both a safety risk and a legal one in WA. Many patients take their THC dose in the evening to avoid this issue. Ask your MedWest pharmacist about the specific regulations that apply to your prescription.
More THC does not always mean better results. There is a well-documented "sweet spot" with THC for anxiety — too much can actually increase anxiety and trigger paranoia, especially in people who are already prone to it. If you feel noticeably worse after starting or increasing your dose, don't push through — contact your pharmacist. The solution is often simply a lower dose or a higher CBD ratio.10
Tell your pharmacist about everything you're taking. Medicinal cannabis interacts with SSRIs, SNRIs, stimulant medications (such as dexamphetamine or methylphenidate), benzodiazepines, and other common psychiatric medicines. Many interactions are manageable with dose adjustment — but your pharmacist needs the full picture. The most common side effects across the research base are dry mouth (32.6%), drowsiness (31.3%), and mild fatigue at higher doses.2
OCD patients — be aware of a nuance. While carefully titrated medicinal cannabis can support OCD treatment, recreational-style cannabis use (particularly at higher, uncontrolled doses) has been linked to worsening OCD symptoms in some people. This is an important distinction. If obsessions or compulsions feel more intense after starting treatment, contact your pharmacist promptly — do not simply push through.3
This medicine is not right for everyone. It is not recommended for people under 25, during pregnancy or breastfeeding, or for those with a personal or family history of psychosis or schizophrenia. Long-term daily THC use in adolescence is associated with measurable adverse effects on brain development and neural connectivity.14
- What CBD-to-THC ratio is best suited to my specific condition — ADHD or OCD?
- Can I take this safely alongside my current medications — SSRI, stimulant, or benzo?
- How will I know if the THC is genuinely helping, or making my anxiety worse?
- Is it safe for me to drive to work or school while on this prescription?
- Should I time my doses around my therapy or psychology sessions?
- What should I do if I experience a panic attack or feel overwhelmed while on this medicine?
www.medwestmedical.com.au
Where This Information Comes From
This guide draws on peer-reviewed research, systematic reviews, and published clinical trials. References are listed in Vancouver format — you don't need to read them, but they're here for transparency and for your healthcare team if needed.
- Goodwin G, Bhatt M, Bhatt S, Bousman C. ADHD in Australia: epidemiology, diagnosis, and treatment — a systematic review. Aust N Z J Psychiatry. 2022;56(9):1089–1105. doi: 10.1177/00048674211065478
- Kayser RR, Snorrason I, Haney M, Lee FS, Simpson HB. The endocannabinoid system: a new treatment target for obsessive compulsive disorder? Cannabis Cannabinoid Res. 2019;4(2):77–87. doi: 10.1089/can.2018.0049
- Ittiphakorn P, Erridge S, Holvey C, et al. UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for attention-deficit/hyperactivity disorder. Neuropsychopharmacol Rep. 2023;43(4):520–530. doi: 10.1002/npr2.12400
- Müller-Vahl KR, Szejko N, Fremer C. Cannabis improves obsessive-compulsive disorder — case report and review of the literature. Front Psychiatry. 2020;11:681. PMC: PMC7396551
- Orsolini L, Chiappini S, Volpe U, et al. Use of medicinal cannabis and synthetic cannabinoids in post-traumatic stress disorder (PTSD): a systematic review. Medicina (Kaunas). 2019;55(9):525. doi: 10.3390/medicina55090525
- de Aquino JP, Sherif M, Radhakrishnan R, Cahill JD, Ranganathan M, D'Souza DC. The psychiatric consequences of cannabinoids. Clin Ther. 2018;40(9):1448–1456. doi: 10.1016/j.clinthera.2018.07.017
- Das RK, Kamboj SK, Ramadas M, et al. Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology (Berl). 2013;226(4):781–792. doi: 10.1007/s00213-012-2955-y
- Ittiphakorn P, Erridge S, Holvey C, et al. UK Medical Cannabis Registry: ADHD outcomes at 12 months. Neuropsychopharmacol Rep. 2023. doi: 10.1002/npr2.12400
- Cooper RE, Williams E, Seegobin S, Tye C, Kuntsi J, Asherson P. Cannabinoids in attention-deficit/hyperactivity disorder: a randomised-controlled trial. Eur Neuropsychopharmacol. 2017;27(8):795–808. doi: 10.1016/j.euroneuro.2017.05.005
- Kayser RR, Haney M, Raskin M, Arout C, Simpson HB. Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: a human laboratory study. Depress Anxiety. 2020;37(8):801–811. PMC: PMC7423713
- Kayser RR, Raskin M, Marcotte M, et al. Nabilone augmentation of exposure and response prevention for obsessive-compulsive disorder: a pilot randomised controlled trial. Depress Anxiety. 2020;37(8):812–818. doi: 10.1002/da.23024

